Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide and a leading cause of death in cirrhosis. The prognosis in HCC is poor, with …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the
fourth most common malignancy and the second leading cause of tumor-related death …

The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Hepatocellular carcinoma is one of the leading causes of cancer related death in the world.
Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of …

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates
and insights - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage
hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of …

The major risk factors for hepatocellular carcinoma (HCC) in contemporary clinical practice
are becoming increasingly related to sustained virological response after hepatitis C …

Background: Primary liver cancer, of which around 75–85% is hepatocellular carcinoma in
China, is the fourth most common malignancy and the second leading cause of tumor …

Background: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but
prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and …